Baxter and Miltenyi Biotec Sign 5-Year Distribution Agreement for Cellular Therapy Products

DEERFIELD, (USA) AND COLOGNE (GERMANY), 24 (PRNewswire)

Baxter Healthcare Corporation and Miltenyi Biotec GmbH announced

today that they have signed an agreement whereby Miltenyi Biotec will

have exclusive rights for five years to distribute, market and sell

Baxter's cellular therapy products worldwide, with the exception of

China, Japan, Korea and Taiwan. Baxter will continue to manufacture

these products. Baxter's cellular therapy products included in the

agreement are the Isolex 300i Magnetic Cell Selection System v2.5,

the Cytomate Cell Processing System, as well as preservation and

expansion bags used for cryopreservation and cell cultures and

biologic reagents.

"We believe that this distribution agreement with Miltenyi is the

best way to keep cell selection, preservation and expansion products

broadly available to customers worldwide," said Jim Utts, general

manager of Baxter Oncology. "Miltenyi Biotec's dedicated focus on

cellular therapies and their global sales force will ensure that our

customers' needs are met." "We are very pleased with the agreement we

have signed with Baxter," said Stefan Miltenyi, managing director for

Miltenyi Biotec. "Not only do these products represent a significant

enhancement to our current portfolio, we also gain immediate access

to the United States, one of the key growth markets for us. We plan

on leveraging our existing distribution infrastructure to continue to

provide customers with the quality products and services they

require."

ABOUT BAXTER

Baxter Healthcare Corporation is the principal domestic operating

subsidiary of Baxter International Inc. (NYSE: BAX). Baxter

International Inc., through its subsidiaries, assists health-care

professionals and their patients with treatment of complex medical

conditions, including cancer, hemophilia, immune disorders, kidney

disease and trauma. The company applies its expertise in medical

devices, pharmaceuticals and biotechnology to make a meaningful

difference in patients' lives.

ABOUT MILTENYI BIOTEC

Miltenyi Biotec GmbH is a diversified biotechnology company

focused on cell separation, molecular biology, GMP manufacturing and

cellular therapies. By combining competencies in biologics and device

technologies, Miltenyi Biotec is uniquely positioned to provide

researchers and clinicians with a wide range of advanced solutions

for cellular research, cell therapies and blood/plasma treatments.

Additional information can be accessed via the web at

http://www.miltenyibiotec.com . Isolex and Cytomate are registered

trademarks of Baxter International Inc. and its affiliates.

Emisor: Baxter Healthcare

FCMN Contact: raquel_powers@baxter.com /

Web site: http://www.baxter.com

http://www.miltenyibiotec.com /

(108271)

Contact: Media, Jan Hoedebecke, +1-847-948-3220, Hans Vanavermaete,

+011-32-478-44-72-78, or Investors, Mary Kay Ladone, +1-847-948-3371,

all of Baxter Healthcare Corporation, or Media and Investors, Tara

Clark of Miltenyi Biotec, +1-781-738-2002

|
24-Sep-2003 16:00:51

(EUROPA PRESS)

09/24/16-00/03
"